While much of the venture capital community has recently pivoted toward artificial intelligence, Max Hodak, the co-founder and former president of Neuralink, has been quietly advancing a different frontier: brain-computer interfaces. His startup, Science Corporation, has now secured a significant milestone in this endeavor, announcing a $230 million Series C funding round on Wednesday. This investment values the company at $1.5 billion post-money, underscoring investor confidence in its ability to bring the first viable brain-computer interface product to market. Science Corp.'s immediate focus is PRIMA, a revolutionary implant designed to restore functional vision to individuals suffering from advanced macular degeneration. The technology consists of a microchip smaller than a grain of rice that is implanted into the eye, working in tandem with specialized camera-equipped glasses. Although Science did not originate the core technology, it acquired the assets of PRIMA from French firm Pixium Vision in 2024. Since the acquisition, Science has refined the device and completed clinical trials, generating its own independent data to validate the system. In trials involving 47 patients across Europe and the United States, the company reports that 80% of participants achieved meaningful improvements in visual acuity. These patients were able to read letters, numbers, and words—a milestone Hodak described as the first definitive demonstration of fluent reading restoration in blind patients. The device has also garnered significant media attention, appearing on the cover of Time magazine. The path to commercialization is well underway. Science Corp. has submitted an application for a CE mark to the European Union and anticipates approval by mid-2026. If granted, the EU launch would position Science as the first BCI company with a commercial product available to patients. Germany is expected to be the first market, leveraging its established pathways for early access to new medical technologies. In the United States, regulatory discussions with the Food and Drug Administration (FDA) are ongoing. To further broaden its impact, the company is expanding its clinical trials to include patients with Stargardt disease and retinitis pigmentosa, both of which are leading causes of vision loss among young adults. The newly raised capital will be allocated to fund the commercialization of PRIMA while supporting a broader research portfolio. Science is actively developing a biohybrid neural interface that involves growing engineered neurons from stem cells onto a waffle-like device placed on the brain's surface, facilitating biological connections with existing neural circuits. Additionally, the company has launched a new venture line called Vessel, an organ preservation platform aiming to develop miniaturized perfusion technology. This innovation seeks to enable the transport of organs via commercial flights and allow patients to maintain organs at home, rather than requiring intensive care unit stays. The Series C round attracted a diverse group of investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT, a nonprofit investment firm focused on government security solutions. With this funding, Science Corp. has accumulated a total of $490 million in investments and currently employs 150 people.